Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Using Fludarabine, Busulfan, 400 cGy Total Body Irradiation, and Thymoglobulin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Sonali Chaudhury, MD
- Phone Number: 312-227-4863
- Email: schaudhury@luriechildrens.org
Study Contact Backup
- Name: Colleen E Rosen, BS, RN
- Phone Number: 312-227-4870
- Email: crosen@luriechildrens.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Contact:
- Sonali Chaudhury, MD
- Phone Number: 312-227-4863
- Email: schaudhury@luriechildrens.org
-
Contact:
- Colleen E Rosen, BS, RN
- Phone Number: 312-227-4870
- Email: crosen@luriechildrens.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 0-21
AML in one of the following stages:
- Having preceding myelodysplasia (MDS)
- High Risk cytogenetics
- Requiring > 2 cycles chemotherapy to obtain complete remission
- High allelic ratio FLT3/ITD+,
- Standard risk cytogenetics with positive MRD at end of Induction
- Second or greater CR
- First relapse with < 25% blasts in bone marrow
- With therapy-related AML whose prior malignancy has been in remission for at least 12 months
- ALL in one of the following stages:
High risk first remission, defined as:
- Ph+ ALL; or,
- MLL rearrangement with slow early response [defined as having M2 (5-25% blasts) or M3 (>25% blasts on bone marrow examination on Day 14 of induction therapy)]; or,
- Hypodiploidy (< 44 chromosomes or DNA index < 0.81); or,
- End of induction M3 bone marrow; or,
- End of induction M2 marrow or MRD>1% with M2-3 marrow or MRD>1% at Day 42.
- High-risk infant ALL defined as age <6 months at diagnosis with MLL (11q23) translocation.
High risk second remission, defined as:
- Bone marrow relapse < 36 months from induction; or >36 mths if a matched sibling donor is available
- T-lineage relapse at any time; or,
- Very early isolated CNS relapse (<18 months from diagnosis); or,
- Slow reinduction (M2-3 at Day 28) after relapse at any time.
- Any third or subsequent CR.
- Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have < 25% blasts in bone marrow
- MDS at any stage; prior therapies allowed
- CML in chronic or accelerated phase; prior therapies allowed
Patient also must have the following organ requirements:
- Adequate renal function defined as serum creatinine <2x normal, or creatinine clearance > 40 ml/min/m^2 or 70 ml/min.
- Adequate liver function as defined by total bilirubin less than or equal to 2 times normal and AST and ALT less than or equal to 4 times normal.
- Adequate cardiac function as defined by: shortening fraction > 24% by echocardiogram, or ejection fraction > 30% by radionuclide angiogram.
- Adequate pulmonary function as defined by DLCO, FEV1/FVC > 60% by pulmonary function tests. For children who are uncooperative for PFTs and have no evidence of dyspnea at rest or exercise intolerance, pulse oximetry > 94% on room air is considered acceptable, with a normal chest xray.
- Adequate venous access; a double lumen central vascular access device or its equivalent and an additional PICC line will be required for all patients.
- Women of childbearing potential and sexually active males should use effective contraception while on study.
Exclusion Criteria:
- Inability to give informed consent or assent
- Inability to obtain a suitable donor
- Patient who is HIV-positive
- Patient who has active Hepatitis B
- Patient who is pregnant
- Patient who is otherwise considered unsuitable for transplant at the discretion of the principal investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: A
All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
|
Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9.
Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2.
The regimen dose of Busulfan will be based off of the findings from their Test Dose.
Other Names:
Patient will receive Fludarabine from Day -6 to Day -2.
The dose of Fludarabine will be 30 mg/m^2/day.
Other Names:
The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2.
Each dose of rabbitATG will be 1.5 mg/kg/day.
On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the toxicity (as measures by 100 day survival) after hematopoietic stem cell transplant from an unrelated donor with a novel preparative regimen.
Time Frame: 100 day mortality
|
100 day mortality
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the relapse-free and overall survival after hematopoietic stem cell transplant with Fludarabine/Busulfan/ATG/TBI preparative regimen for pediatric patients with leukemia.
Time Frame: 5 years
|
5 years
|
|
To evaluate the incidence of acute and chronic graft-versus-host disease after hematopoietic stem cell transplant
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sonali Chaudhury, MD, Ann & Robert H Lurie Children's hospital of Chicago
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Fludarabine
- Busulfan
- Thymoglobulin
Other Study ID Numbers
Other Study ID Numbers
- SCT 0208
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.